Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19898838 | 1.00 | HTR2C (0.48) | HTR2CALDH1A1MEN1KMT2APREP | |
| SCHEMBL19898320 | 0.92 | ALDH1A1 (0.48) | HTR2CALDH1A1MEN1KMT2APREP | |
| SCHEMBL19910781 | 0.84 | HTR2C (0.47) | HTR2CALDH1A1MEN1KMT2APREP | |
| SCHEMBL19898539 | 0.84 | HTR2C (0.47) | HTR2CALDH1A1MEN1KMT2APREP | |
| SCHEMBL19898733 | 0.84 | HTR2C (0.47) | HTR2CALDH1A1MEN1KMT2APREP | |
| SCHEMBL18410564 | 0.84 | HTR2C (0.57) | HTR2CALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9546620 | 0.84 | HTR2C (0.57) | HTR2CALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12976063 | 0.79 | ALDH1A1 (0.50) | HTR2CALDH1A1MEN1KMT2APREP | |
| SCHEMBL18410486 | 0.78 | HTR2C (0.57) | HTR2CALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10332200 | 0.78 | SMN1; SMN2 (0.50) | HTR2CALDH1A1MEN1KMT2APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | BTK, SYK, LCK | HTR2C 2931/4885ALDH1A1 3677/4885MEN1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.